Antitumor agents: development of highly potent glycosidic duocarmycin analogues for selective cancer therapy.
about
Design, synthesis, and evaluation of duocarmycin O-amino phenol prodrugs subject to tunable reductive activationA five-membered lactone prodrug of CBI-based analogs of the duocarmycinsA novel, unusually efficacious duocarmycin carbamate prodrug that releases no residual byproduct.A unique class of duocarmycin and CC-1065 analogues subject to reductive activation.Efficacious cyclic N-acyl O-amino phenol duocarmycin prodrugs.Synthesis and biological evaluation of a novel pentagastrin-toxin conjugate designed for a targeted prodrug mono-therapy of cancer.Glucose conjugation for the specific targeting and treatment of cancer.Peptide modified mesoporous silica nanocontainers.New thiazacridine agents: Synthesis, physical and chemical characterization, and in vitro anticancer evaluation.Determination of the biological activity and structure activity relationships of drugs based on the highly cytotoxic duocarmycins and CC-1065The first generation of β-galactosidase-responsive prodrugs designed for the selective treatment of solid tumors in prodrug monotherapy.Duocarmycin analogues target aldehyde dehydrogenase 1 in lung cancer cells.A galactosidase-responsive "trojan horse" for the selective targeting of folate receptor-positive tumor cells.Selective treatment of hypoxic tumor cells in vivo: phosphate pre-prodrugs of nitro analogues of the duocarmycins.Investigation of the transformations of a novel anti-cancer agent combining HPLC, HPLC-MS and direct ESI-HRMS analyses.Novel hypoxia-targeting Pt(iv) prodrugs.The two faces of potent antitumor duocarmycin-based drugs: a structural dissection reveals disparate motifs for DNA versus aldehyde dehydrogenase 1 affinity.
P2860
Q34279769-FAF52AD3-368D-4E1F-B8A1-512409B6B676Q35694557-C25445C3-DFA3-4347-BA9E-A009DEFB3C13Q36067092-7D5869E3-F29A-4453-979F-A9FABFF75F1DQ36846628-E13AFAB2-2EC1-4FBF-A1C7-2D4FAE47B5FEQ36943532-434D7A3F-9C0E-4915-ABCA-52C93CD374EBQ37083440-CD1C878D-8FB6-47C3-9959-353D507D4C32Q37200539-F6514747-56D7-4089-9E60-66CC4C0ABBB0Q37487102-CB0FFA70-D188-4793-A18B-1BC0F7A1D215Q38789715-44C24BB4-5F18-40A1-AAE9-7A0552870286Q38842518-C039E9EE-AF90-41A3-8BBB-5B0C928EBADAQ39274501-0F9498A7-321D-41DF-AA7F-642F162AF0B9Q39396571-F4F371CE-9870-4E80-A625-D0EFBCB50355Q39569531-B9840BB0-B898-49BF-9029-2F143B27262EQ39582426-87E01B38-0831-42EE-890F-386A2CE38438Q42215830-C54480FB-840E-4936-A305-158FAF999A3BQ48113171-9DDE196B-5F2D-4215-8D12-954DE38F1233Q50987490-92866898-F123-4606-8C0E-11CFE1328C59
P2860
Antitumor agents: development of highly potent glycosidic duocarmycin analogues for selective cancer therapy.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Antitumor agents: development ...... for selective cancer therapy.
@en
type
label
Antitumor agents: development ...... for selective cancer therapy.
@en
prefLabel
Antitumor agents: development ...... for selective cancer therapy.
@en
P2093
P356
P1476
Antitumor agents: development ...... for selective cancer therapy.
@en
P2093
Felix Major
Ingrid Schuberth
Lutz F Tietze
P2860
P304
P356
10.1002/ANIE.200600936
P407
P577
2006-10-01T00:00:00Z